市場調查報告書

細菌性感染疾病治療藥的全球市場(2020年∼2027年)

Global Bacterial Infectious Diseases Therapeutics Market - 2020-2027

出版商 DataM Intelligence 商品編碼 968994
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
細菌性感染疾病治療藥的全球市場(2020年∼2027年) Global Bacterial Infectious Diseases Therapeutics Market - 2020-2027
出版日期: 2020年11月04日內容資訊: 英文
簡介

全球細菌性感染疾病治療藥市場,由於老年人的細菌性感染疾病發病風險高,及隨著老年人增加需求也提高。還有藥物抗性病原體的出現和擴大,抗生素抗藥性高漲,推動在預測期間內治療藥的開發。根據世界衛生組織(WHO)的新全球抗菌藥監測系統(GLASS),在22個國家的50萬懷疑細菌感染者中已觀察到抗生素耐藥性。

本報告提供全球細菌性感染疾病治療藥市場的相關調查,市場機會,成長及阻礙因素,法規、償付分析,COVID-19的影響,各疾病類型、治療藥、給藥途徑、流通管道、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 市場定義和概要

第3章 摘要整理

  • 各疾病類型
  • 各治療藥物
  • 各給藥途徑
  • 各流通管道
  • 各地區

第4章 市場動態

  • 影響市場的要素
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 產業分析

  • 波特的五力分析
  • 流行病學
  • 開發平台分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 COVID-19的影響分析

  • 市場上的Covid-19分析
  • Covid-19的價格動態
  • 需求與供給的頻譜
  • 大流行時的市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 市場分析:各疾病類型

  • 簡介
  • 市場規模分析,及與前一年同期比較成長分析
  • 市場魅力指數
    • 細菌性皮膚感染疾病
    • 食物中毒菌感染疾病
    • 細菌性性感染疾病
    • 其他

第8章 市場分析:各治療藥物

  • 簡介
  • 市場規模分析,及與前一年同期比較成長分析
  • 市場魅力指數
    • β-內醯胺
    • 奎諾酮類抗生素(Quinolones)
    • 大環內酯類
    • 四環黴素
    • 磺胺類藥物
    • 其他

第9章 市場分析:各給藥途徑

  • 簡介
  • 市場規模分析,及與前一年同期比較成長分析
  • 市場魅力指數
    • 口服
    • 局部
    • 非口服
    • 其他

第10章 市場分析:各流通管道

  • 簡介
  • 市場規模分析,及與前一年同期比較成長分析
  • 市場魅力指數
    • 醫院藥局
    • 零售藥局
    • 線上藥局
    • 其他

第11章 市場分析:各地區

  • 簡介
  • 市場規模分析,及與前一年同期比較成長分析
  • 市場魅力指數
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東和非洲

第12章 競爭情形

  • 競爭模式
  • 市場地位/佔有率分析
  • 合併和收購分析

第13章 企業簡介

  • Novartis AG*
  • GlaxoSmithkline plc
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Sanofi
  • Allergan
  • Bayer AG
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Baxter
  • Eli Lilly and Company
  • Johnson and Johnson
  • Insmed, Inc.
  • Otsuka Pharmaceuticals Co., Ltd.
  • Roche Holding AG
  • Forest Laboratories, Inc.
  • Teva Pharmaceuticals Industries Ltd.

第14章 重要考察

第15章 DataM

  • 附錄
  • 關於本公司、服務
  • 諮詢方式
目錄

Market Overview

Bacterial infectious diseases are the infectious diseases occurred due to bacteria that trigger a protective immune response. It involves the proliferation of a harmful strain of bacteria on or inside the body. Bacteria are the single-celled microorganisms found in all sorts of environments, including soil, water bodies, and in or on other bodies. Bacteria are present in different shapes including the rod-shaped (bacilli), spherical (cocci), or helical (spirilla).

Bacterial infectious diseases can affect the throat, lungs, skin, bowel and other body parts. Bacterial infectious diseases are characterized by the various signs and symptoms including the bloody urine, frequent urination, diarrhea, fatigue, fever, sore throat, headache, cough, aches, nausea, vomiting, rashes, lesions, abscesses, weakness, and others. Bacterial infectious diseases increase the risk of causing life-threatening complications, such as blood poisoning, kidney failure, toxic shock syndrome, and others.

The global bacterial infectious diseases therapeutics market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Market Dynamics

Growing Older Population is Driving the Growth of the Market

The demand of the bacterial infectious diseases therapeutics is increasing with the rising older population as the older population is at the high risk of developing the bacterial infectious diseases. Severe bacterial infectious diseases are observed among the older population due to several factors such as medical conditions, weakened immune system, concurrent use of different drugs, delayed diagnosis, delayed or diminished response to therapy.

According to the United Nations (UN) report, the older population of age-group 65 years or above was 703 million worldwide in 2019. The older population is expected to be more than double and reach up to 1.5 billion in 2050. Asia has higher older population in comparision to the Europe and Northern America. Urinary tract infections, skin infections, gastrointestinal infections, pneumonia, influenza, and others are most frequent among the older population.

Increasing Antibacterial Resistance is Expected to boost the Development of Therapeutics over the Forecast Period.

There is growing antibacterial resistance due to the emergence and spread of drug-resistant pathogens. According to the World Health Organization (WHO)'s new Global Antimicrobial Surveillance System (GLASS), the antibiotic resistance was observed among 500,000 people with suspected bacterial infections across 22 countries. Approximately, 3.4% of new TB cases and 18% of previously treated cases had MDR-TB/ RR-TB in 2018.

Several factors such as misuse and overuse of antibacterials, lack of access to clean water, sanitation and hygiene (WASH), poor infection and disease prevention and control in health-care facilities, poor access to quality, affordable medicines, vaccines and diagnostics, lack of awareness and knowledge, and lack of enforcement of legislation are causing the antibacterial resistance. The antibacterial resistance is limiting the treatment of the most frequent bacterial infectious diseases. There is rising spread of multi- and pan-resistant bacteria infection not being treatable by using the existing antibacterials worldwide.

The increasing antibacterial resistance has resulted in rising development of the therapeutics for the treatment of bacterial infectious diseases. The pipeline of bacterial infectious diseases is robust with the involvement of the several therapeutics being developed. Several companies are developing the therapeutics that is effective in overcoming the resistance demonstrated by existing antibacterials. According to the World Health Organization (WHO), there are approximately 32 antibiotics in clinical development that address the WHO list of priority pathogens. Out of these 32 antibiotics in pipeline, only six were classified as innovative.

Rising Organizations & Institutes Intiatives for Overcoming the Antibacterial Resistance is Fueling the Market Growth

Several organizations & institutes have raised the intiatives for overcoming the antibacterial resistance. For instance, in October 2015, the World Health Organization (WHO) has launched the Global Antimicrobial Resistance Surveillance System (GLASS) for supporting the global action plan on antimicrobial resistance that aims to support global surveillance and research for strengthening the evidence base on antimicrobial resistance (AMR). World Health Organization (WHO) had entered into the Global Antibiotic Research and Development Partnership (GARDP) with the the Drugs for Neglected Diseases Initiative (DNDi). This partnership aims at developing and delivering the five new treatments that target drug-resistant bacteria identified by WHO as posing the greatest threat by 2025.

The United States Food and Drug Administration (FDA) has passed the Generating Antibiotic Incentives Now (GAIN) act for addressing the public health threat of antibacterial drug resistance by stimulating the development and approval of new antibacterial and antifungal drugs.

COVID-19 Impact Analysis

The bacterial infectious diseases therapeutics has witnessed the drastic growth with the increasing number of the people suffering from the COVID-19 as the antibacterials are being used for the treatment of bacterial infections among the patients with COVID-19. Various bacteria species such as Staphylococcus spp., Enterococcus spp., Klebsiella pneumoniae, Enterobacter spp., Escherichia coli, Acinetobacter spp., and Pseudomonas spp are causing the infection among the patients with COVID-19.

According to the Bradley J. Langford et.al., 2020 study published in clinical microbiology & infection (CMI), bacterial co-infection was observed among 3.5% of COVID-19 patients and 14.3% of COVID-19 patients. Approximately, 71.9% of COVID-19 patients received antibiotics for the treatment of bacterial infections. Antibiotics such as azithromycin, ceftriaxone, quercetin, rapamycin, doxycycline, and other antibiotics are mostly recommended among the patients. Azithromycin has demonstrated the anti-inflammatory effects that can be useful for reducing an overactive immune response to COVID-19.

Epidemiology

According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, the prevalence of the Rheumatoid Arthritis (RA) was found to be 395.5 per 100,000 in the United States in 2017. Women are two to three times as likely to be affected in comparision to the men. It has been observed that around one in 12 women and one in 20 men would develop an inflammatory autoimmune rheumatic disease during their life. According to Giegerich E et.al. 2018, the diagnosed prevalence of Crohn's Disease was 6 cases per 100,000 in lower-income Asia-Pacific, 46 cases per 100,000 in high-income Asia-Pacific, 133 cases per 100,000 in Europe, and 210 cases per 100,000 in North America in 2017. The diagnosed prevalence of Crohn's Disease is highest among people of age-group 40-54 years. The prevalence of ankylosing spondylitis was observed to be 23.8 per 10,000 in Europe, 16.7 per 10,000 in Asia, 31.9 10,000 in North America, 10.2 10,000 in Latin America and 7.4 per 10,000 in Africa.

Segment Analysis

Beta-Lactam segment is expected to hold the largest share in the Bacterial Infectious Diseases Therapeutics market

By therapeutics, the market is classified as the beta-lactam, quinolones, macrolides, tetracyclines, sulfonamide, and others. Beta-lactam segment is anticipated to hold the largest share as it is most most prescribed antibacterials for for the prevention & treatment of the bacterial infection. The beta-lactam acts by inhibiting the ell wall synthesis. It targets the penicillin-binding proteins (PBPs) involved in the cross-linking of the bacterial cell wall. B-Lactam antibiotics is effective against the broad range of clinical indications. Penicillins, cephalosporins, carbapenems, and monobactams are the beta-lactam antibacterials with the highest market penetration.

There is increasing research and development activities for the beta-lactam therapeutics. For instance, in March 2019, Iterum Therapeutics had received Qualified Infectious Disease Product (QIDP) and Fast Track Designations from the United States Food and Drug Administration (FDA) for its oral and intravenous (IV) formulations of sulopenem in four new indications including the community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory disease. Sulopenem had also received the Qualified Infectious Disease Product (QIDP) and Fast Track Designations for the treatment of uncomplicated urinary tract infection (uUTI), complicated urinary tract infection (cUTI), and complicated intra-abdominal infection (cIAI).

By Distribution Channel, Retail Pharmacies Segment is Expected to Witness a High Growth Over the Forecast Period

The market is classified on the distribution channel as the hospital pharmacies, retail pharmacies, online pharmacies and others. The retail pharmacies is segmented to have the highest market growth due to the high availability of the therapeutics for the treatment of the bacterial infectious diseases in the retail pharmacies & drug stores. There is increase in the number of the retail stores across the globe. According to the cross-sectional survey conducted from the August to October 2014, approximately 93.5% of antibiotics including the amoxicillin and trimethoprim-sulfamethoxazole were prescribed by majority of the registered drug shops.

Geographical Analysis

North America region holds the largest market share global Bacterial Infectious Diseases Therapeutics market

North America region is dominating the global bacterial infectious diseases therapeutics market accounted for the largest market share in 2019 owing to the increasing prevalence of the bacterial infectious diseases. According to the Centers for Disease Control and Prevention (CDC), the incidence cases of tuberculosis was 9,105 in the United States in 2017. The total number of incidence cases of salmonella and Lyme disease was 54,285 and 42,743 respectively in the United States in 2017. There is growing prevalence of the antibacterial resistant infection. According to the Centers for Disease Control and Prevention (CDC), every year more than 2.8 million people were affected by the antibiotic-resistant infections in 2019. Every year more than 35,000 people died due to antibiotic-resistant infections.

The United States accounts for the highest market share due to the higher usage of the therapeutics for the treatment of bacterial infectious diseases. According to the Centers for Disease Control and Prevention (CDC), the healthcare providers had prescribed 270.2 million antibiotic prescriptions i.e., 836 antibiotic prescriptions per 1000 persons. There is rising approval & launch of the therapeutics for the treatment of bacterial infectious diseases. For instance, in October 2018, Paratek Pharmaceuticals, Inc. had received the approval for the Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). In August 2018, Tetraphase Pharmaceuticals, Inc. had received the approval from the United States Food and Drug Administration (FDA) for the Xerava (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI). The easy availabilities of the antibacterial shall stimulate the market growth over the forecasted period.

Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period

Asia-Pacific region is estimated to be the fastest-growing region in the global bacterial infectious disease therapeutics market owing to the increasing prevalence of the bacterial infectious diseases with the increasing older population. According to the United Nations Report, there were around 87millions of population of age-group 65 years or over in India. The increasing investment for the improvement of the healthcare facilities & infrastructure shall have a positive impact on the market.

There is increasing research and development activities for the development of the therapeutics for the treatment of bacterial infectious diseases. There is presence of the several market players developing the therapeutics for the treatment of bacterial infectious diseases. There is growing awareness regarding the use of the antibacterial for the treatment of bacterial infection. The increasing domestic income and purchasing power of people shall boost the demand for bacterial infectious diseases therapeutics over the forecasted period.

Competitive Landscape

The bacterial infectious diseases therapeutics market studied is a fragmented market with the presence of large number of market players. Novartis AG, GlaxoSmithkline Plc, Pfizer Inc, Merck & Co., Inc., Sanofi, Allergan, Bayer AG, AstraZeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Johnson and Johnson, and Teva Pharmaceuticals Industries Ltd. are the major market players with the significant market share. Companies are adopting several growth strategies such as product approvals, product launches, acquisitions, mergers, collaborations, and licensing for increasing their market presence. For instance,

Mergers & Collaborations:

  • In July 2019, Nosopharm had entered into the collaboration with Evotec SE for advancing the NOSO-502, a novel antibiotic class against Enterobacteriace infections to the clinical stage of development and developing a second-generation Odilorhabdin for the treatment of hospital-acquired pneumonia and ventilation-associated pneumonia (HAP/VAP)
  • In April 2018, AiCuris had entered into the collaboration with the Max Planck Institute of Molecular Physiology (MPI) for discovering the new antibacterial drugs to treat viral and bacterial infections. Under the terms of agreement, the AiCuris would gain access to MPI's proprietary collection of natural product-based compounds. This collaboration would be useful for discovery and development of innovative approaches to fight bacterial and viral resistance.
  • In February 2014, Roche had entered into the collaboration with Discuva for the development of the new antibiotics. Under the terms of agreement, Roche would be using the Discuva's Selective Antibiotic Target IdentificatioN (SATIN) for discovering and developing the new antibiotics for infections caused by multi-drug resistant Gram-negative bacteria. Under the terms of agreement, Roche would pay Discuva $16 million upfront, plus up to $175 million per product developed, based on achieving undisclosed development, commercialization and sales milestones. Discuva would also receive royalties on sales of products developed through its collaboration WITH Roche's Pharma Research and Early Development (pRED).

Product Launch & Approvals:

  • In July 2019, Merck & Co. had received the approval from the United States Food and Drug Administration (FDA) for the Recarbrio (imipenem, cilastatin, and relebactam) injection, 1.25 grams, a new combination antibacterial. Recarbrio is recommended for the patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms such as Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
  • In July 2019, Merck & Co. had received the approval for Zerbaxa (ceftolozane and tazobactam) from the United States Food and Drug Administration (FDA) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.
  • Allergan plc had received the approval to expand the use of Avycaz (ceftazidime and avibactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms including the Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae in patients 18 years of age or older.

Acquisition:

  • In February 2020, Grifols had acquired the Aradigm, an antibiotic developer.
  • In January 2018, Melinta Therapeutics, Inc. had acquired The Medicines Company's infectious disease business. This acquisition would help the company to provide the world-class infectious disease portfolio led by renowned experts in antibiotics discovery, development, and commercialization.
  • In December 2016, Pfizer Inc. had acquired the development and commercialization rights to AstraZeneca's late-stage small molecule anti-infective business, primarily outside the United States. Under the terms of agreement, Pfizer had acquired the commercialization and development rights to the newly approved EU drug Zavicefta (ceftazidime-avibactam), the marketed agents Merrem /Meronem (meropenem) and Zinforo (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL.

Why Purchase the Report?

  • Visualize the composition of the bacterial infectious disease therapeutics market segmentation by disease type, and distribution channel highlighting the key commercial assets and players.
  • Identify commercial opportunities in Bacterial Infectious Diseases Therapeutics market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Bacterial Infectious Diseases Therapeutics market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global bacterial infectious diseases therapeutics market report would provide an access to an approx. 61 market data table, 58 figures and 230 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Bacterial Infectious Diseases Therapeutics Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Bacterial Infectious Diseases Therapeutics Market - Market Definition and Overview

3. Global Bacterial Infectious Diseases Therapeutics Market - Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Therapeutics
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Global Bacterial Infectious Diseases Therapeutics Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Older Population
      • 4.1.1.2. Increasing Prevalence of Bacterial Infectious Diseases
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Adverse Effects of Therapeutics
      • 4.1.2.2. Genetic Mutations
      • 4.1.2.3. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Bacterial Infectious Diseases Therapeutics Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. Global Bacterial Infectious Diseases Therapeutics Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Bacterial Infectious Diseases Therapeutics Market - By Disease Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
  • 7.3. Market Attractiveness Index, By Disease Type Segment
    • 7.3.1. Bacterial Skin Infections*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Foodborne Bacterial Infections
    • 7.3.3. Sexually Transmitted Bacterial Infections
    • 7.3.4. Others

8. Global Bacterial Infectious Diseases Therapeutics Market - By Therapeutics

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
  • 8.3. Market Attractiveness Index, By Therapeutics Segment
    • 8.3.1. Beta-Lactam*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Quinolones
    • 8.3.3. Macrolides
    • 8.3.4. Tetracyclines
    • 8.3.5. Sulfonamide
    • 8.3.6. Others

9. Global Bacterial Infectious Diseases Therapeutics Market - By Route of Administration

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3. Market Attractiveness Index, By Route of Administration Segment
    • 9.3.1. Oral*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Topical
    • 9.3.3. Parenteral
    • 9.3.4. Others

10. Global Bacterial Infectious Diseases Therapeutics Market - By Distribution Channel

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3. Market Attractiveness Index, By Distribution Channel Segment
    • 10.3.1. Hospitals Pharmacies*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
    • 10.3.4. Others

11. Global Bacterial Infectious Diseases Therapeutics Market - By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Global Bacterial Infectious Diseases Therapeutics Market - Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Global Bacterial Infectious Diseases Therapeutics Market- Company Profiles

  • 13.1. Novartis AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. GlaxoSmithkline plc
  • 13.3. Pfizer Inc.
  • 13.4. Merck & Co., Inc.
  • 13.5. Sanofi
  • 13.6. Allergan
  • 13.7. Bayer AG
  • 13.8. AstraZeneca Plc
  • 13.9. Bristol-Myers Squibb Company
  • 13.10. Takeda Pharmaceutical Company Limited
  • 13.11. Baxter
  • 13.12. Eli Lilly and Company
  • 13.13. Johnson and Johnson
  • 13.14. Insmed, Inc.
  • 13.15. Otsuka Pharmaceuticals Co., Ltd.
  • 13.16. Roche Holding AG
  • 13.17. Forest Laboratories, Inc.
  • 13.18. Teva Pharmaceuticals Industries Ltd.

LIST NOT EXHAUSTIVE

14. Global Bacterial Infectious Diseases Therapeutics Market - Premium Insights

15. Global Bacterial Infectious Diseases Therapeutics Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us